Anti-TSLP monoclonal antibody (mAb) Tezepelumab (AMG157/MEDI9929) has first been reported in 2014 and is to date the most prominent and advanced inhibitor of TSLP-mediated signaling in the context of allergic inflammatory disorders and the only TSLP-linked antagonistic candidate that is currently in phase III clinical trial in patients with severe asthma (136–138). The gene discussed is TSLP; the disease is asthma.